By Fineline Cube Xinno Biotechnology (Jiashan) Co., Ltd. announced an exclusive technology collaboration agreement with US‑based Statia Biopharma, Inc. to jointly develop an innovative transdermal formulation of STA528, a novel drug candidate for autoimmune diseases. The partnership covers both formulation product development (PD) and global business development (BD).
Deal Overview
| Item | Detail |
|---|---|
| Parties | Xinno Biotechnology (Jiashan) Co., Ltd. × Statia Biopharma, Inc. |
| Deal Type | Exclusive technology collaboration |
| Asset | STA528 – transdermal formulation |
| Scope | Formulation product development (PD) + global business development (BD) |
| Platform | Xinno Bio’s proprietary HETDS (High‑Efficiency Transdermal Delivery System) |
| Target Indications | Rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PsA), systemic lupus erythematosus (SLE) |
| Announcement Date | 10 Aug 2026 |
Drug Profile & Mechanism of Action
- Molecule: STA528, lead candidate of Statia Biopharma, a US biotech focused on innovative therapies for autoimmune diseases
- Target: Phospho‑Specific STAT3 – a novel mechanism of action
- Mechanism: Inhibits the inflammatory signaling pathway mediated by STAT3 phosphorylation, thereby modulating aberrant immune responses
- Differentiation: Offers a differentiated, first‑in‑class‑style approach distinct from traditional JAK inhibitor therapies
Clinical Evidence – Phase 2 (US, Ulcerative Colitis)
| Dimension | Outcome |
|---|---|
| Study Status | Phase 2 completed in the US |
| Efficacy | Favorable clinical efficacy demonstrated |
| Safety | Favorable safety profile observed |
| Key Advantage | Avoided adverse effects commonly associated with traditional JAK inhibitors |
The Phase 2 readout provides a clinical foundation for expanding STA528 into additional autoimmune indications via a transdermal route.
Technology Platform – HETDS
- Proprietary System: Xinno Bio’s High‑Efficiency Transdermal Delivery System (HETDS)
- Objective: Optimize STA528’s pharmacokinetic properties and safety profile through transdermal delivery
- Potential Benefits: Improved exposure control, reduced systemic side effects, and enhanced patient compliance versus oral dosing
Market Impact & Outlook
- Indication Breadth: RA, psoriasis, PsA and SLE collectively represent multi‑billion‑dollar global autoimmune markets with significant unmet need for safer chronic therapies.
- Safety Positioning: A STAT3‑pathway inhibitor that avoids JAK‑inhibitor‑class adverse effects could be attractive to physicians and payers seeking differentiated risk profiles.
- Strategic Fit: The deal pairs Statia’s novel mechanism asset with Xinno’s transdermal delivery expertise — a structure designed to support both formulation innovation and global out‑licensing optionality.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the collaboration’s development plans, formulation outcomes, and commercial potential for STA528. Actual results may differ due to risks including clinical outcomes, regulatory pathways, and competitive dynamics.-Fineline Info & Tech